L24 drugs used in COPD Flashcards

(42 cards)

1
Q

COPD

A

chronic obstructive pulmonary disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

COPD affects more than ____ of the US adult population

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

COPD is the _____ leading cause of death in US in 2018

A

4th

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

_____- of COPD pateints are smokers

A

85%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

COPD irreversible airflow obstruction due to

A

emphysema
chronic bronchitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

COPD symptoms

A

-chronic cough
-sputum
-dyspnea
-barrel chest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

emphysema

A

-permanent enlargement of bronchioles and alveoli due to destruction of their walls
-dyspnea due to insufficient gas exchange
-cigarette smoking is the major cause
-frequently asymptomatic until the later stage of life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

patholphysiology of emphysema

A

tissue damage by proteases
oxidative injury by reactive oxygen species (ROS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

tissue damage by proteases

A

-irritants in cigarette smoke cause inflammation in alveoli.
-Neutrophils and macrophages accumulate.
-Activated neutrophils and macrophages release proteases (ex. neutrophil
elastase), resulting tissue damage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

oxidative injury by reactive oxygen species (ROS)

A

-ROS in cigarette smoke deplete antioxidants in the lungs (ex. superoxide
dismutase, glutathione).
-ROS inactivate ⍺1-antitrypsin, which normally suppresses the protease activities.
-Activated neutrophils also release ROS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

alpha 1-antitrypsin

A

-Protease inhibitor produced in the liver (53 kDa)
-Inhibits neutrophil elastase.
-Limits lung tissue damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

alpha 1-antitrypsin deficiency

A

-Rare genetic disorder leading to insufficient ⍺1-Antitrypsin activity
-increased neutrophil migration
-Increased lung damage via inflammation and protease activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

chronic bronchitis

A

-chronic inflammation in bronchial tubes
(mucus hypersecretion and fibrosis and narrowing of airways)
-frequently coexists with emphysema
-cigarette smoking is the major cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

symptoms of chronic bronchitits

A

-producing cough
-wheezing
-shortness of breathe/ chest pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

pathophysiology of chronic bronchitis

A

-Initiated by the exposure to irritants (cigarette smoke or other air pollutants)
 Hypersecretion of the bronchial mucous glands.
 Hypertrophy of mucous glands
 Metaplastic formation of mucin-secreting goblet cells
 Inflammation with infiltration of CD8+ T cells, macrophages, and neutrophils (no involvement of eosinophils)
-Microbial infection may paly a secondary role in maintaining inflammation and
exacerbating symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

tissue remodeling in COPD

A

-Fibrosis of small airways
-Hyperinflation of lungs:
 Alveolar enlargement
 Alveolar wall destruction
-Mucus hypersecretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

asthma vs COPD in site

A

asthma; proximal airways
COPD; peripheral airways

17
Q

asthma vs COPD in onset

A

asthma; childhood
COPD; late adulthood

18
Q

asthma vs COPD in symptoms

A

asthma; episodic attack
COPD; progressive deterioration of pulmonary function

19
Q

cells affects in asthma vs COPD

A

asthma: mast cells, eosinophils, CD4+ T cells
COPD; neutrophils, macrophages, CD8+ T cells

20
Q

key mediators in asthma vs COPD

A

asthma: IL-4, IL-5, IL-13
COPD; IL-8, TNF-alpha, IL-1b, IL-6

21
Q

nonpharmacological therapy treatment of COPD

A

-Smoking cessation
-Exercise
-Immunization
-Long-term oxygen therapy

22
Q

pharmacological therapy in treatment of COPD

A

-Bronchodilators
 β2 selective agonists (short-acting, long-acting, and ultra-long-acting)
-Antimuscarinic agents (short-acting and long-acting)
-Methylxanthines
-Corticosteroids for patients with exacerbations
-alpha 1-antitrypsin replacement therapy (rare)

23
Q

beta 2 selective agonist: short-acting (SABA)

A

-Albuterol, levalbuterol
-Repid onset, but the response is less than seen in asthma.

24
beta 2 selective agonist long acting (LABA)
-Salmetrol, formoterol -Every 12 hours -Not for acute relief of symptoms
25
beta 2 selective agonist: ultra long acting (Ultra LABA)
-Indacaterol, olodaterol, vilanterol, bambuterol -Once a day -Can be used as monotherapy for COPD (not for asthma). -Combination  Fluticasone furoate/vilanterol
26
antimuscarinic agents: short acting (SAMA)
-ipratropium -As effective as albuterol in patients with COPD
27
antimuscarinic agents: long acting (LAMA)
-Tiotropium, aclidinium, umeclidinium -Once a day -Approved for maintenance therapy of COPD. -Quaternary amine salt like ipratropium -Combination  Fluticasone furoate/umeclidinium bromide/vilanterol
28
mathylxantines
-Once considered first-line therapy for COPD. -Mostly replaced by LABA and antimuscarinics. -Theophylline
29
methylxantines: theoohylline
 Used in patients who are intolerant to or cannot use inhaled bronchodilators.  Bronchodilation and anti-inflammatory action  Systemic administration may be beneficial on peripheral airways
30
roflumilast
 Phosphodiesterase-4 (PDE4) inhibitor  Increases the intracellular cAMP concentration as methylxanthines.  Suppresses the release of cytokines and chemokines  Approved for COPD, but not for asthma
31
corticosteroids uses in COPD
-Short-term systemic use for acute exacerbations -inhalation therapy for chronic stable COPD
32
mechanisms of cortiosteroids
 Decrease mucus release by reducing capillary permeability  Suppress protease release from immune cells  Suppress prostaglandin production
33
alpha 1-antitrypsin replacement therapy: products
-Derived from donated blood -Prolastin® , Aralast®, Zemaira®
34
alpha 1- antitrypsin replacement therapy
-Reduces lung tissue loss and destruction in patients with severe ⍺1-Antitrypsin deficiency. -Expensive (>$50k a year)
35
short acting beta 2 selective agonist (SABA)
-Albuterol -Levalbuterol (Xopenex®)
36
long acting beta 2 selective agonist (LABA)
-Salmetrol (Serevent ®) -Formoterol
36
ultra long acting beta 2 selective agonists
-Indacaterol (Arcapta® ) -Olodaterol (Strieverdi®) -Vilanterol ( -Bambuterol (Bambec ®, Oxeol ®)
36
methylxanthine
theophylline
36
antimuscarinic
-Ipratropium (Atrovent ®) -Tiotropium (Spiriva ®) -Aclidinium (Tudorza ®, Pressair®) -Umeclidinium (Incruse Ellipta ®)
36
PDE4 inhibitor
Roflumilast (Daliresp ®)
36
combinations
-Fluticasone furoate/vilanterol (Breo Ellipta ®) -Fluticasone furoate/umeclidinium bromide/vilanterol (Trelegy Ellipta ®)